TNF-alpha -308G>A Polymorphism Modulates Cytokine Serum Concentrations and Macrovascular Complications in Diabetic Patients on Aspirin

Abstract

Background: Tumor necrosis factor (TNF)-α has pleiotropic effects in cytokine-mediated inflammation underlying atherogenesis. Activation of this inflammatory process is assumed to be different in diabetic and non-diabetic individuals. Previous studies in non-diabetic subjects showed no association between TNF-α -308G>A polymorphism and coronary artery disease.

Methods: Vascular complications and cytokine serum concentrations were assessed as a function of the TNF-α -308G>A polymorphism in 76 diabetic patients on low-dose aspirin.

Results: Of 76 adult diabetic patients, 18 (24%) carried the TNF-α -308A allele (17 AG, 1 AA) and 58 (76%) carried wild-type alleles (GG). Prevalence of macrovascular complications was 33% in TNF-α -308A allele carriers (AG+AA) and 78% in wild-type allele carriers (GG) (p<0.001). In contrast, prevalence of microvascular complications was 78% and 84%, respectively, and did not significantly differ between the study groups. TNF-α -308A allele carriers (AG+AA) compared to wild-type allele carriers (GG) had significantly lower median serum concentrations of hs-C-reactive protein (1.5 vs 2.9 mg/L, p=0.030), interleukin 1-β (0.9 vs 1.2 ng/L, p=0.046), and interleukin-6 (3.6 vs 4.9 ng/L, p=0.023). In multiple regression analysis, the prevalence of macrovascular diabetic complications was significantly associated with TNF-α -308G>A polymorphism (p<0.001) and serum concentrations of HDL-cholesterol (p=0.007) while confounding effects of further variables were excluded.

Conclusion: TNF-α -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Diabetic carriers of the TNF-α -308A allele might benefit more from a prophylaxis with low dose aspirin than non-carriers.

Key words

Diabetes mellitus - TNF-alpha - aspirin - cardiovascular events - hs-C-reactive protein - hs-CRP

References

• 1 Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease.  J Leukoc Biol. 1999;  66 562-566
• 2 Albertini JP, Valensi P, Lormeau B, Aurousseau MH, Ferriere F, Attali JR, Gattegno L. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes.  Care. 1998;  21 1008-1013
• 3 Altarescu G, Zimran A, Michelakakis H, Elstein D. levels and TNF-alpha gene polymorphism in type I Gaucher disease.  Cytokine. 2005;  31 149-152
• 4 Antithrombotic Trialists’ Collaboration: . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
• 5 Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forester JS. Detection and localization of tumor necrosis factor in human atheroma.  Am J Cardiol. 1990;  65 297-302
• 6 Ceriello A, Motz E. Prevention of vascular events in diabetes mellitus: which “antithrombotic” therapy?.  Diabetologia. 1996;  39 1405-1406
• 7 Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes.  Diabetes. 2005;  54 97-107
• 8 Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events.  Diabetes Care. 2003;  26 2181-2188
• 9 Colwell JA. Aspirin therapy in diabetes.  Diabetes Care. 2004;  27 ((Suppl 1)) S72-73
• 10 Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, Crossman DC. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease.  Circulation. 1999;  99 861-866
• 11 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation.  N Engl J Med. 1999;  340 448-454
• 12 Gao J, Shan G, Sun B, Thompson PJ, Gao X. Association between polymorphism of tumour necrosis factor {alpha}-308 gene promoter and asthma: a meta-analysis.  Thorax. 2006;  61 466-471
• 13 Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A, Fuentes D, Nino P, Cadahia V, Saro C, Dieguez MA, Lopez-Larrea C. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease.  Am J Gastroenterol. 2003;  98 1101-1106
• 14 Gordon MA, Oppenheim E, Camp NJ, di Giovine FS, Duff GW, Gleeson D. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region.  J Hepatol. 1999;  31 242-247
• 15 Haffner SM. Coronary heart disease in patients with diabetes.  N Engl J Med. 2000;  342 1040-1042
• 16 Hajeer AH, Hutchinson IV. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease.  Hum Immunol. 2001;  62 1191-1199
• 17 Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications.  Cardiol Rev. 2006;  14 18-25
• 18 Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis.  Arteriosclerosis. 1989;  9 567-578
• 19 Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A, Ruidavets JB, Luc G, Bara L, Parra HJ, Poirier O, Cambien F. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity.  Eur J Clin Invest. 1998;  28 59-66
• 20 Jones DE, Watt FE, Grove J, Newton JL, Daly AK, Gregory WL, Day CP, James OF, Bassendine MF. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis.  J Hepatol. 1999;  30 232-236
• 21 Kaartinen M, Penttilä A, Kovanen PT. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-α.  Circulation. 1996;  94 2787-2792
• 22 Kallas EG, Reynolds K, Andrews J, Treanor JJ, Evans TG. Production of influenza-stimulated tumor necrosis factor-alpha by monocytes following acute influenza infection in humans.  J Interferon Cytokine Res. 1999;  19 751-755
• 23 Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading.  Nat Genet. 2003;  33 469-475
• 24 Knopp RH, Retzlaff B, Aikawa K, Kahn SE. Management of patients with diabetic hyperlipidemia.  Am J Cardiol. 2003;  91 ((7A)) 24E-28E
• 25 Koch W, Kastrati A, Bottiger C, Mehilli J, von Beckerath N, Schomig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction.  Atherosclerosis. 2001;  159 137-144
• 26 Krayenbuehl P, Maly FE, Hersberger M, Wiesli P, Himmelmann A, Eid K, Greminger P, Vetter W, Schulthess G. Tumor Necrosis Factor-α -308G>A polymorphism modulates iron accumulation in patients with hereditary hemochromatosis.  Clin Chem. 2006;  52 1552-1558
• 27 Krikovszky D, Vasarhelyi B, Toth-Heyn P, Korner A, Tulassay T, Madacsy L. Association between -308G>A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents.  Clin Genet. 2002;  62 474-477
• 28 Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?.  Diabetes. 2005;  54 ((Suppl 2)) S114-124
• 29 Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription.  Mol Immunol. 1997;  34 391-399
• 30 Kutuk O, Basaga H. Aspirin inhibits TNFalpha- and IL-1-induced NF-kappaB activation and sensitizes HeLa cells to apoptosis.  Cytokine. 2004;  25 229-237
• 31 Libby P. Molecular bases of the acute coronary syndromes.  Circulation. 1995;  91 2844-2850
• 32 Majetschak M, Obertacke U, Schade FU, Bardenheuer M, Voggenreiter G, Bloemeke B, Heesen M. Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients.  Clin Diagn Lab Immunol. 2002;  9 1205-1211
• 33 Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein.  Diabetes Care. 2005;  28 690-693
• 34 McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria.  Nature. 1994;  371 508-510
• 35 Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut JF. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study.  JAMA. 1999;  282 561-568
• 36 Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients.  Diabetes. 1997;  46 2096-2101
• 37 Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women.  N Engl J Med. 2004;  351 2599-2610
• 38 Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes.  Am J Cardiol. 2001;  88 ((suppl)) 10K-15K
• 39 Roberts WL. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: laboratory tests available to assess inflammation-performance and standardization: a background paper.  Circulation. 2004;  110 e572-576
• 40 Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G. Nicolucci A; PPP Collaborative Group . Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.  Diabetes Care. 2003;  26 3264-3272
• 41 Schaaf BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, Maass M, Zabel P, Dalhoff K. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism.  Am J Respir Crit Care Med. 2003;  168 476-480
• 42 Schiekofer S, Franke S, Andrassy M, Chen J, Rudofsky G, Schneider JG, von Eynatten M, Wendt T, Morcos M, Kientsch-Engel R, Stein G, Schleicher E, Nawroth PP, Bierhaus A. Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal.  Exp Clin Endocrinol Diabetes. 2006;  114 160-167
• 43 Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes.  Diabetes Care. 2004;  27 889-894
• 44 Shin HD, Park BL, Kim LH, Jung JH, Wang HJ, Kim YJ. et al . Association of tumor necrosis factor polymorphisms with asthma and serum total IgE.  Hum Mol Genet. 2004;  13 397-403
• 45 Sookoian S, Garcia SI, Gianotti TF, Dieuzeide G, Gonzalez CD, Pirola CJ. The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome.  Am J Hypertens. 2005;  18 1271-1275
• 46 Staiger H, Häring HU. Adipocytokines: Fat-derived humoral mediators of metabolic homeostasis.  Exp Clin Endocrinol Diabetes. 2005;  113 67-79
• 47 Tsiavou A, Hatziagelaki E, Chaidaroglou A, Manginas A, Koniavitou K, Degiannis D, Raptis A. TNF-α, TGF-β, IL-6, gene polymorphisms in latent autoimmune diabetes of adults and type 2 diabetes mellitus.  J Clin Immunol. 2004;  24 591-599
• 48 Vatay A, Rajczy K, Pozsonyi E, Hosszufalusi N, Prohaska Z, Füst G, Karadi I, Szalai C, Grosz A, Bartfai Z, Panczel P. Differences in the genetic backgroud of latent autoimmune diabetes in adults and type 1 diabetes mellitus.  Immunol Lett. 2002;  84 109-115
• 49 Vendrell J, Fernandez-Real JM, Gutierrez C, Zamora A, Simon I, Bardaji A, Ricart W, Richart C. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients.  Atherosclerosis. 2003;  167 257-264
• 50 Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.  Proc Natl Acad Sci USA. 1997;  94 3195-3199
• 51 Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes.  N Engl J Med. 2002;  347 1916-1923
• 52 Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)-beta.  Nature. 1988;  396 77-80
• 53 Zeggini E, Groves CJ, Parkinson JR, Halford S, Oven KR, Frayling TM. et al . Large-scale studies of the association between variations at the TNF/LTA locus and susceptibility to type 2 diabetes.  Diabetologica. 2005;  48 2013-2017
• 54 Zipperlen K, Peddle L, Melay B, Hefferton D, Rahman P. Association of TNF-alpha polymorphisms in Crohn disease.  Hum Immunol. 2005;  66 56-59

Correspondence